ARTSaVIT

Company Overview

Snapshot

Founded in February 2014 by Sarit Larisch, ARTSaVIT operates with 1–10 employees. The company has raised $6.3M across two funding rounds from five investors. In January 2017, ARTSaVIT secured funding from Carmel-Haifa University Economic Corporation and Carmel Innovation Fund.

Business overview

ARTSaVIT is a Health Tech & Life Sciences company focused on developing a molecular mechanism of apoptosis induced by apoptotic-related tumor suppressors (ARTS). The company's core technology aims to determine how ARTS binding to inhibitors of apoptosis proteins and other apoptotic regulators leads to caspase activation and cell death. ARTSaVIT operates within the framework of the Merck Ventures Israel BioIncubator, serving the pharmaceuticals, oncology, and biotechnology sectors with a focus on cancer treatment.

Strategic signal

In January 2017, ARTSaVIT announced it had raised $6.3 million, a significant capital infusion that validated its research into cancer apoptosis technology. This funding signaled investor confidence in the company's approach to developing novel anticancer drugs by targeting the molecular mechanisms of cell death, positioning it for further R&D in the oncology space.

Company Intelligence Q&A

What is ARTSaVIT's primary focus?

ARTSaVIT is developing a molecular mechanism of apoptosis induced by apoptotic-related tumor suppressors (ARTS) to identify and screen small-molecule ARTS mimetics for anticancer drugs.

When was ARTSaVIT founded?

ARTSaVIT was founded in February 2014.

Which investors participated in ARTSaVIT's January 2017 funding round?

In January 2017, ARTSaVIT received funding from Carmel-Haifa University Economic Corporation and Carmel Innovation Fund.

What was a key milestone for ARTSaVIT in January 2017?

In January 2017, ARTSaVIT raised $6.3 million to advance its cancer treatment research.

What is the current status of ARTSaVIT?

ARTSaVIT is currently non-active and ceased to operate in June 2018.